Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Tarceva Dose Escalation in Current Smokers: Could Higher Doses Improve Results?
Author
Howard (Jack) West, MD

We have long noted that there is a clear association of smoking history with effectiveness of oral EGFR tyrosine kinase inhibitors (TKIs). Part of this is because never-smokers have a high incidence of carrying activating EGFR mutations, but also potentially because current smokers actually metabolize EGFR TKIs faster (see prior post). We've seen a consistent association of rash development with better outcome (see prior post), and current smokers have been disproportionately likely to develop little or no rash. A recent study just coming out in the Journal of Clinical Oncology from a group in the UK has studied blood levels with dose escalation of tarceva (erlotinib) among current smokers (abstract here) and suggests a possible value in giving higher than standard tarceva dosing among current smokers, so that they can achieve the same blood levels as never-smokers or former smokers. Will this lead to better results for these patients?

The clinical trial enrolled patients who smoked at least 10 cigarettes per day and first escalated the dose of tarceva from 200 to 350 mg daily and carefully assessed side effects. While the standard "maximum tolerated dose" with tarceva in a general population is 150 mg/day, this population of current smokers reached the level of frequent rash and diarrhea and fatigue at 300 mg/day. One thing this work demonstrated was that escalating the dose could bring current smokers to the side effect severity and frequency more typical of never-smokers or prior smokers.

The trial then entered another phase that enrolled 35 current smokers to receive either the standard dose of 150 mg/day or 300 mg/day. Looking at the blood levels in patients, the higher dose translated to higher blood levels, which are comparable to the levels of people who don't smoke:

erlotinib PK in Smokers (click to enlarge)

Interestingly, the patients who received the higher dose of tarceva had a median pverall survival of 9.56 months, compared with 5.45 months for current smokers who received tarceva at 150 mg/day (pretty similar to the median overall survival of 6.1 months in the larger BR.21 trial of tarceva vs. placebo (abstract here).

However, we need to keep the results of this small trial in perspective. This trial had just a few dozen patients, so comparison of very small groups is only provocative, not conclusive at all. It suggests that there is a value in asking the question of whether escalating dose in current smokers might be benefcial. But the BR.21 trial didn't show a better result in former smokers (median overall survival 5.5 months) than current smokers, and the former smokers shouldn't be metabolizing tarceva faster and getting lower blood levels: interestingly, the package insert for tarceva says that doctors might consider giving a higher dose than the standard 150 mg to current smokers, but we just don't have much evidence to guide us here. And at about $3500/month for tarceva at the standard dose, I can imagine many insurers balking at doubling that cost based on something that is a mere hypothesis waiting to be tested more thoroughly. But at least the little work done thus far suggests that we might improve outcomes for smokers receiving tarceva by re-evaluating whether they're receiving the best dose right now.

Next Previous link

Previous PostNext Post

Related Content

Image
Blood Cancers OncTalk 2024
Video
  This event was moderated by Dr. Sridevi Rajeeve, Memorial Sloan Kettering, joined by speakers: Dr. Hamza Hashmi, Memorial Sloan Kettering, Dr. Michele Stanchina, University of Miami, Dr. Muhammad Salman Faisal, Oklahoma University, and Dr. Andrew Srisuwananukorn, Ohio State University Topics include: - Myeloma 101: Facts and Fiction of the 'Myeloma Marathon' - Updates in DLBCL - Treatment Basics of Bone Marrow Transplant - Frontline Therapies in Myelofibrosis - Panel Discussions and a Question-and-Answer session
Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.

Forum Discussions

Hi Stan,

It's so good to hear you and yours are doing well and that you were able to spend time with both families for Thanksgiving.  I know it meant a...

Hi Stan!  It is good to hear from you -- I am so very happy you are doing well.  I agree with Janine that family and friends - our chosen family...

Recent Comments

JOIN THE CONVERSATION
Hey Bluebird,

I understand…
By JanineT GRACE … on
So good to hear from you Stan
By dbrock on
Hi Stan,

It's so good to…
By JanineT GRACE … on